BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang XT, Guo W, Sun M, Han W, Du ZH, Wang XX, Du BB, Bai O. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report. World J Clin Cases 2020; 8(14): 3122-3129 [PMID: 32775395 DOI: 10.12998/wjcc.v8.i14.3122]
URL: https://www.wjgnet.com/2307-8960/full/v8/i14/3122.htm
Number Citing Articles
1
Jingyu Song, Jie Liu, Dan Guo, Huibo Li, Shengjin Fan. Chidamide maintenance therapy after allo-HSCT in SET-NUP214 fusion positive T-ALL patients: A report of two casesTransplant Immunology 2024; 87: 102119 doi: 10.1016/j.trim.2024.102119
2
TucidinostatReactions Weekly 2020; 1824(1): 267 doi: 10.1007/s40278-020-84235-2
3
Jia Liu, Jian Chen Fang, Lu Zhong. Effective treatment with programmed cell death protein‐1 antibody, chidamide and conventional chemotherapy for hepatosplenic γδ T‐cell lymphoma: A case report and literature reviewJournal of Digestive Diseases 2022; 23(1): 50 doi: 10.1111/1751-2980.13068
4
Susann Schönefeldt, Tamara Wais, Marco Herling, Satu Mustjoki, Vasileios Bekiaris, Richard Moriggl, Heidi A. Neubauer. The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive LymphomaCancers 2021; 13(24): 6212 doi: 10.3390/cancers13246212